Desmethylbellidifolin Attenuates Dextran Sulfate Sodium-Induced Colitis: Impact on Intestinal Barrier, Intestinal Inflammation and Gut Microbiota

Abstract

Ulcerative colitis has been recognized as a chronic inflammatory disease predominantly disturbing the colon and rectum. Clinically, the aminosalicylates, steroids, immunosuppressants, and biological drugs are generally used for the treatment of ulcerative colitis at different stages of disease progression. However, the therapeutic efficacy of these drugs does not satisfy the patients due to the frequent drug resistance. Herein, we reported the anti-ulcerative colitis activity of desmethylbellidifolin, a xanthone isolated from Gentianella acuta, in dextran sulfate sodium-induced colitis in mice. C57BL/6 mice were treated with 2% dextran sulfate sodium in drinking water to induce acute colitis. Desmethylbellidifolin or balsalazide sodium was orally administrated once a day. Biological samples were collected for immunohistological analysis, intestinal barrier function evaluation, cytokine measurement, and gut microbiota analysis. The results revealed that desmethylbellidifolin alleviated colon shortening and body weight loss in dextran sulfate sodium-induced mice. The disease activity index was also lowered by desmethylbellidifolin after 9 days of treatment. Furthermore, desmethylbellidifolin remarkably ameliorated colonic inflammation through suppressing the expression of interleukin-6 and tumor necrosis factor-α. The intestinal epithelial barrier was strengthened by desmethylbellidifolin through increasing levels of occludin, ZO-1, and claudins. In addition, desmethylbellidifolin modulated the gut dysbiosis induced by dextran sulfate sodium. These findings suggested that desmethylbellidifolin effectively improved experimental ulcerative colitis, at least partly, through maintaining intestinal barrier integrity, inhibiting proinflammatory cytokines, and modulating dysregulated gut microbiota.

Key words

desmethylbellidifolin - Gentianella acuta - Gentianaceae - ulcerative colitis

Publikationsverlauf

Eingereicht: 29. Januar 2021

Angenommen nach Revision: 01. Mai 2021

Artikel online veröffentlicht:
07. Juni 2021

• References

• 1 Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet 2017; 389: 1756-1770
• 2 Gyde S, Prior P, Dew MJ, Saunders V, Waterhouse JA, Allan RN. Mortality in ulcerative colitis. Gastroenterology 1982; 83: 36-43
• 3 Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017; 390: 2769-2778
• 4 Kou FS, Shi L, Li JX, Wang ZB, Shi R, Mao TY, Ke X, Zhang BP, Yang XJ, Wen XL, Zheng WY, Han X, Ding PH, Dong J. Clinical evaluation of traditional Chinese medicine on mild active ulcerative colitis: A multi-center, randomized, double-blind, controlled trial. Medicine (Baltimore) 2020; 99: e21903
• 5 Guan Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res 2019; 2019: 7247238
• 6 Cao SY, Ye SJ, Wang WW, Wang B, Zhang T, Pu YQ. Progress in active compounds effective on ulcerative colitis from Chinese medicines. Chin J Nat Med 2019; 17: 81-102
• 7 Pang Y, Guan W, Hu X, Gao Y, Li J. Research advance on chemical constituents and pharmacological effects of Gentianella acuta . Chinese Traditional and Herbal Drugs 2018; 49: 5468-5476
• 8 Ni Y, Liu M, Yu H, Chen Y, Liu Y, Chen S, Ruan J, Da A, Zhang Y, Wang T. Desmethylbellidifolin from Gentianella acuta ameliorate TNBS-induced ulcerative colitis through antispasmodic effect and anti-inflammation. Front Pharmacol 2019; 10: 1104
• 9 Camilleri M, Madsen K, Spiller R, Greenwood-Van Meerveld B, Verne GN. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil 2012; 24: 503-512
• 10 Reinisch W, Gasche C, Tillinger W, Wyatt J, Lichtenberger C, Willheim M, Dejaco C, Waldhor T, Bakos S, Vogelsang H, Gangl A, Lochs H. Clinical relevance of serum interleukin-6 in Crohnʼs disease: Single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol 1999; 94: 2156-2164
• 11 Singh UP, Singh NP, Murphy EA, Price RL, Fayad R, Nagarkatti M, Nagarkatti PS. Chemokine and cytokine levels in inflammatory bowel disease patients. Cytokine 2016; 77: 44-49
• 12 Gren ST, Grip O. Role of monocytes and intestinal macrophages in Crohnʼs disease and ulcerative colitis. Inflamm Bowel Dis 2016; 22: 1992-1998
• 13 Ahmed J, Reddy BS, Molbak L, Leser TD, MacFie J. Impact of probiotics on colonic microflora in patients with colitis: a prospective double blind randomised crossover study. Int J Surg 2013; 11: 1131-1136
• 14 Kang M, Martin A. Microbiome and colorectal cancer: Unraveling host-microbiota interactions in colitis-associated colorectal cancer development. Semin Immunol 2017; 32: 3-13
• 15 Aye A, Song YJ, Jeon YD, Jin JS. Xanthone suppresses allergic contact dermatitis in vitro and in vivo . Int Immunopharmacol 2020; 78: 106061
• 16 Wang W, Liao Y, Huang X, Tang C, Cai P. A novel xanthone dimer derivative with antibacterial activity isolated from the bark of Garcinia mangostana . Nat Prod Res 2018; 32: 1769-1774
• 17 Miladiyah I, Jumina J, Haryana SM, Mustofa M. Biological activity, quantitative structure-activity relationship analysis, and molecular docking of xanthone derivatives as anticancer drugs. Drug Des Devel Ther 2018; 12: 149-158
• 18 Lu NH, Zhao HQ, Jing M, Liu X, Ren CZ, Liu XF, Liu JJ, Zhang YX. The pharmacodynamic active components study of Tibetan medicine Gentianopsis paludosa on ulcerative colitis fibrosis. Int Immunopharmacol 2017; 46: 163-169
• 19 Dou W, Zhang J, Ren G, Ding L, Sun A, Deng C, Wu X, Wei X, Mani S, Wang Z. Mangiferin attenuates the symptoms of dextran sulfate sodium-induced colitis in mice via NF-kappaB and MAPK signaling inactivation. Int Immunopharmacol 2014; 23: 170-178
• 20 Wirtz S, Popp V, Kindermann M, Gerlach K, Weigmann B, Fichtner-Feigl S, Neurath MF. Chemically induced mouse models of acute and chronic intestinal inflammation. Nat Protoc 2017; 12: 1295-1309
• 21 Oh SY, Cho KA, Kang JL, Kim KH, Woo SY. Comparison of experimental mouse models of inflammatory bowel disease. Int J Mol Med 2014; 33: 333-340
• 22 Rocco A, Compare D, Angrisani D, Sanduzzi Zamparelli M, Nardone G. Alcoholic disease: liver and beyond. World J Gastroenterol 2014; 20: 14652-14659
• 23 Perse M, Cerar A. Dextran sodium sulphate colitis mouse model: traps and tricks. J Biomed Biotechnol 2012; 2012: 718617
• 24 Johansson MEV, Gustafsson JK, Holmen-Larsson J, Jabbar KS, Xia LJ, Xu H, Ghishan FK, Carvalho FA, Gewirtz AT, Sjovall H, Hansson GC. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut 2014; 63: 281-291
• 25 Andoh A, Imaeda H, Aomatsu T, Inatomi O, Bamba S, Sasaki M, Saito Y, Tsujikawa T, Fujiyama Y. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohnʼs disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol 2011; 46: 479-486
• 26 Mishima Y, Sartor RB. Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseases. J Gastroenterol 2020; 55: 4-14
• 27 Guo SS, Geng WY, Chen S, Wang L, Rong XL, Wang SC, Wang TF, Xiong LY, Huang JH, Pang XB, Lu YM. Ginger alleviates DSS-induced ulcerative colitis severity by improving the diversity and function of gut microbiota. Front Pharmacol 2021; 12: 632569
• 28 Vich Vila A, Imhann F, Collij V, Jankipersadsing SA, Gurry T, Mujagic Z, Kurilshikov A, Bonder MJ, Jiang X, Tigchelaar EF, Dekens J, Peters V, Voskuil MD, Visschedijk MC, van Dullemen HM, Keszthelyi D, Swertz MA, Franke L, Alberts R, Festen EAM, Dijkstra G, Masclee AAM, Hofker MH, Xavier RJ, Alm EJ, Fu J, Wijmenga C, Jonkers D, Zhernakova A, Weersma RK. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Sci Transl Med 2018; 10: aap8914
• 29 Lambe jr. DW. Serology of Bacteroidaceae. In: Lambe jr. DW, Genco RJ, Mayberry-Carson KL. eds. Anaerobic Bacteria. Boston: Springer; 1980: 141-153
• 30 Hofstad T. Serological responses to antigens of bacteroidaceae. Microbiol Rev 1979; 43: 103-115
• 31 Eribe ERK, Olsen I. Leptotrichia species in human infections II. J Oral Microbiol 2017; 9: 1368848
• 32 Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98: 694-702
• 33 Hu X, Xu N, Yang X, Hu X, Zheng Y, Zhang Q. Nigella A ameliorates inflammation and intestinal flora imbalance in DSS induced colitis mice. AMB Express 2020; 10: 179
• 34 Rhee KJ, Wu S, Wu X, Huso DL, Karim B, Franco AA, Rabizadeh S, Golub JE, Mathews LE, Shin J, Sartor RB, Golenbock D, Hamad AR, Gan CM, Housseau F, Sears CL. Induction of persistent colitis by a human commensal, enterotoxigenic Bacteroides fragilis, in wild-type C57BL/6 mice. Infect Immun 2009; 77: 1708-1718
• 35 Liu H, Hong XL, Sun TT, Huang XW, Wang JL, Xiong H. Fusobacterium nucleatum exacerbates colitis by damaging epithelial barriers and inducing aberrant inflammation. J Dig Dis 2020; 21: 385-398
• 36 Liu Y, Ni Y, Ruan J, Qu L, Yu H, Han L, Zhang Y, Wang T. Bioactive gentixanthone and gentichromone from the whole plants of Gentianella acuta (Michx.) Hulten. Fitoterapia 2016; 113: 164-169
• 37 Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc 2007; 2: 541-546
• 38 Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58: 1091-1103
• 39 He W, Liu MY, Li YM, Yu HY, Wang D, Chen Q, Chen Y, Zhang Y, Wang T. Flavonoids from Citrus aurantium ameliorate TNBS-induced ulcerative colitis through protecting colonic mucus layer integrity. Eur J Pharmacol 2019; 857: 172456
• 40 Gori M, Altomare A, Cocca S, Solida E, Ribolsi M, Carotti S, Rainer A, Francesconi M, Morini S, Cicala M, Guarino MPL. Palmitic acid affects intestinal epithelial barrier integrity and permeability in vitro . Antioxidants (Basel) 2020; 9: 417